
|Articles|July 9, 2015
- Gastrointestinal Cancers (Issue 5)
- Volume 4
- Issue 2
Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials
Author(s)Axel Grothey, MD
Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.
Advertisement
Articles in this issue
about 11 years ago
Prevention and Screening of CRCabout 11 years ago
Survival Differences in KRAS/BRAF Mutations in mCRCabout 11 years ago
New Agents Show Potency for Patients with HCCabout 11 years ago
Success of Regorafenib Confirmed in Patients With mCRCabout 11 years ago
Agents Under Examination Demonstrate Success in Gastric CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5


























